Awen Gallimore

Awen Gallimore

Auto-generated profile, based on publicly available information

Awen Gallimore

Division of Infection and Immunity, School of Medicine, Cardiff University , Cardiff CF14 4XN

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 1998 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
AGAwen Gallimore
Awen Gallimore
AGAnn Glithero
Ann Glithero
AGAndrew Godkin
Andrew Godkin
ATAlain C. Tissot
Alain C. Tissot
APAndreas Plückthun
Andreas Plückthun
RZRolf Zinkernagel
Rolf Zinkernagel
This study describes the construction of soluble major histocompatibility complexes consisting of the mouse class I molecule, H-2Db, chemically biotinylated β2 microglobulin and a peptide epitope derived from the glycoprotein (GP; amino acids 33–41) of lymphocytic choriomeningitis virus (LCMV). Tetrameric class I complexes, which were produced by mixing the class I complexes with phycoerythrin-labeled neutravidin, permitted direct analysis of virus-specific cytotoxic T lymphocytes (CTLs) by flow cytometry. This technique was validated by (a) staining CD8+ cells in the spleens of transgenic mice that express a T cell receptor (TCR) specific for H-2Db in association with peptide GP33–41, and (b) by staining virus-specific CTLs in the cerebrospinal fluid of C57BL/6 (B6) mice that had been infected intracranially with LCMV-DOCILE. Staining of spleen cells isolated from B6 mice revealed that up to 40% of CD8+ T cells were GP33 tetramer+ during the initial phase of LCMV infection. In contrast, GP33 tetramers did not stain CD8+ T cells isolated from the spleens of B6 mice that had been infected 2 mo previously with LCMV above the background levels found in naive mice. The fate of virus-specific CTLs was analyzed during the acute phase of infection in mice challenged both intracranially and intravenously with a high or low dose of LCMV-DOCILE. The results of the study show that the outcome of infection by LCMV is determined by antigen load alone. Furthermore, the data indicate that deletion of virus-specific CTLs in the presence of excessive antigen is preceded by TCR downregulation and is dependent upon perforin.

1 January 1995 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SRSarah Rowland-Jones
Sarah Rowland-Jones
JSJulian Sutton
Julian Sutton
KAKoya Ariyoshi
Koya Ariyoshi
TDTao Dong
Tao Dong
FGFrances Gotch
Frances Gotch
HWHilton Whittle
Hilton Whittle

1 November 2000 in Vaccine
Verified
Journal Article
Closed access
MRMichael J Roy
Michael J Roy
MWMary S Wu
Mary S Wu
LBLori James Barr
Lori James Barr
JFJames T Fuller
James T Fuller
LTLynda G Tussey
Lynda G Tussey
Deborah FullerDeborah Fuller
Deborah Fuller

1 April 2002 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MKManfred Kopf
Manfred Kopf
BABrian Abel
Brian Abel
AGAwen Gallimore
Awen Gallimore
MCMichael Carroll
Michael Carroll
MBMartin F. Bachmann
Martin F. Bachmann

1 December 1999 in Immunity
Verified
Journal Article
Closed access
MKManfred Kopf
Manfred Kopf
CRChristiane Ruedl
Christiane Ruedl
NSNicole Schmitz
Nicole Schmitz
AGAwen Gallimore
Awen Gallimore
KLKarin Lefrang
Karin Lefrang
MBMartin F Bachmann
Martin F Bachmann

28 October 2002 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
DGDenise Golgher
Denise Golgher
EJEmma Jones
Emma Jones
FPFiona Powrie
Fiona Powrie
TETim Elliott
Tim Elliott
AGAwen Gallimore
Awen Gallimore
Although it is known that the immune system can mount responses to a variety of tumors it is clear that most tumors exhibit weak or even undetectable immunogenicity. Recent findings suggest that the lack of tumor immunogenicity is partly due to a population of cells called CD4+CD25+ regulatory T cells since depletion of these cells in mice can result in tumor rejection.These cells have also been shown to inhibit the development of organ‐specific autoimmune diseases suggesting that they inhibit immune responses to tissue‐specific self‐antigens. Such immune responses may also mediate tumor rejection. Alternatively, immune responses in mice depleted of regulatory cells may target tumor antigens that are not tissue‐specific, but which are shared by tumors of diverse origins. In experiments performed to discriminate between these possibilities we found, using the murine colorectal tumor CT26, that tumor immunity stimulated in the absence of regulatory cells is not restricted to tumors of colorectal origin, but is effective against tumors of different histological types such as B cell lymphomas and a renal cell carcinoma. By comparing this to CT26‐induced immunity through the use of adjuvant we show that the generation of cross‐reactive tumor immunity is a specific manifestation of CD25+ regulatory cell depletion. The generation of CD4+T cells capable of mediating tumor rejection is another important feature of tumor immunity induced in the absence of CD25+ cells.